Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Age of Blood in Sickle Cell Transfusion
NCT03704922Phase 3Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Oct 2017
- Primary completion
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes, Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of red blood cells in sickle cell disease (SCD) (2 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Proportion of Biochemically Old Red Cell Units. Started Oct 2017; status: completed.
02
Drugs
red blood cells
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03704922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03704922.